At the same time, Tempus sorts through clinical data from doctors, hospitals, and studies to standardize the information and analyze for patterns. Tempus, a tech start-up set up by Groupon founder Eric Lefkofsky, has announced that is has raised $110m for its personalised cancer treatments. Founded in 2015, the investment brings the company's total funding to $320m, along with a valuation of $2bn. The company says it will use this money to develop and commercialise new treatments based around gene therapy - which involves altering genes so they can be used as weapons against cancer. In a press release, Tempus said the new funding would be used to expand its technology into new treatment areas, beyond cancer, as well as to grow geographically.
Tempus, a tech start-up set up by Groupon founder Eric Lefkofsky, has announced that is has raised $110m for its personalised cancer treatments. Founded in 2015, the investment brings the company's total funding to $320m, along with a valuation of $2bn. The company says it will use this money to develop and commercialise new treatments based around gene therapy - which involves altering genes so they can be used as weapons against cancer. In a press release, Tempus said the new funding would be used to expand its technology into new treatment areas, beyond cancer, as well as to grow geographically.